Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

Phase 2TerminatedNCT04468230

Virginia Commonwealth University4 enrolled

Overview

Assess the efficacy of short-term nicotine transdermal patch administration for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) in cancer stable patients or patients in remission.

This phase 2 study will test the efficacy of short-term transdermal nicotine transdermal patch administration in patients who have been diagnosed with CIPN. The study will follow an open-label, crossover within-subjects clinical trial design with nicotine transdermal patch.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Neuropathy Peripheral Neuropathy Neuropathic Pain Chemotherapy-induced Peripheral Neuropathy

Interventions

Nicotine Transdermal PatchDRUG

Nicotine Treatment Condition

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically diagnosed peripheral sensory neuropathy defined as: * Greater than Grade 1 peripheral sensory neuropathy using the CTCAE v5.0 grading scale * Grade 1 Asymptomatic * Grade 2 Moderate symptoms; limiting instrumental activities of daily living (ADL) * Grade 3 Severe symptoms; limiting self-care ADL * Grade 4 Life-threatening consequences; urgent intervention indicated * Have a baseline chemotherapy-induced peripheral neuropathy (CIPN) patient reported outcome (PRO) total sensory score ≥ 24.3 on a 19 to 76 scale using the European Organization for Research and Treatment of Cancer Quality of Life-CIPN20 Questionnaire (EORTC QLQ-CIPN-20) * Have a CIPN-related neuropathic pain score ≥ 4 on a 0 to 10 scale using the Brief Pain Inventory-Short Form (BPI-SF) item 5 * Will not have used any nicotine or tobacco products (eg, cigarettes, electronic cigarettes, smokeless tobacco, or other nicotine replacement therapies) within 14 days prior to study treatment start date * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Not currently receiving any chemotherapy * Have previously received platinum- and/or taxane-based chemotherapy treatments and have persistent pain at least 3 months after completion of treatments. * Willing and able to comply with study procedures and visit schedule. * Willing to abstain from all tobacco/nicotine product use during study treatment and 30-day follow-up period. * Ability to self-apply or have the patch applied at home daily. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * History of pre-existing peripheral sensory neuropathies related to the following: * Autoimmune disease * B12/folate deficiency * Diabetes Mellitus * Human immunodeficiency virus (HIV) * Hyper/hypothyroidism * Monoclonal gammopathy of undetermined significance or multiple myeloma * History of receiving other types of neurotoxic chemotherapy drugs (eg, vinca alkaloids, bortezomib, thalidomide) * Current or prior pheochromocytoma * History of or active or clinically significant cardiac disease including any of the following: * Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment * Myocardial infarction diagnosed within 6 months prior to initiating study treatment * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers * New York Heart Association (NYHA) class III or IV congestive heart failure * Poorly controlled high or low blood pressure defined as: * Systolic blood pressure (SBP) ≥ 140; Diastolic blood pressure (DBP) ≥ 90 * SBP ≤ 90; DBP ≤ 60 * Regular use of the following medications: * Varenicline * Bupropion (ie, bupropion hydrochloride sustained release) * Women will be excluded if they are breastfeeding or are pregnant (by urinalysis) within 14 days prior to the start of nicotine transdermal patch administration. * Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Locations (2)

Virginia Commonwealth University

Richmond, Virginia, United States

VCU Community Memorial Healthcenter

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Efficacy of Short-term Nicotine Transdermal Patch Administration in the Treatment of Cancer Induced Peripheral Neuropathy (CIPN)

To assess the efficacy, of the nicotine transdermal patch administration in the treatment of CIPN in patients whose cancer is stable or in remission as defined by a ≥ 2.7 point decrease in the total sensory score of the European Organization for Research and Treatment of Cancer Quality of Life-cancer induced peripheral neuropathy (CIPN20) Questionnaire (EORTC QLQ-CIPN-20) (eg, an improvement in the patients quality of life by one grade). The QLQ-CIPN20 numerical score has a range of 19-76, in which lower scores indicate less symptoms and a better quality of life.

Time frame: 79 Days

Secondary Outcomes

Efficacy of Pain-related Changes and Degree of Functional Interference in the Treatment of CIPN

To assess the efficacy of short-term nicotine transdermal patch administration in the treatment of CIPN in patients whose cancer is stable or in remission by assessing changes in the degree of pain-related functional interference measured by the Brief Pain Inventory - Short Form (BPI-SF) interference score. The BPI-SF contains 4 items assessing average, worst, least, and immediate pain severity in the last 24 hours. Pain severity items are scored using an 11-point numeric rating scale (0, no pain; 10, pain as bad as you can imagine). Seven BPI-SF items will be used to quantify the degree to which pain interferes with daily activities or function (0, does not interfere; 10, completely interferes). The 7 items are summed to obtain a total interference score.

Time frame: 79 Days

Number of Participants at Risk and Affected by Adverse Events (AEs) Related to the Transdermal Nicotine Patch.

To assess the AEs profile of nicotine transdermal patch administration for the treatment of CIPN in patients whose cancer is stable or in remission. The Adverse events (AEs) are reported using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version (CTCAE v 5.0)

Time frame: 79 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.